Sonablate Corp.

LONDON--( BUSINESS WIRE )--The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch. Focused ultrasound is a groundbreaking platform technology that uses ultrasound energy guided by real-time imaging to treat tissue deep in the body, without incisions or radiation. The Foundation will celebrate its launch with an event being held on 31 January at the House of Lords with important guests including MPs, members of the House of Lords, business leaders, and experts from medical charities and some of the UK’s leading research institutions, including the Institute of Cancer Research, Oxford University, and Imperial, King’s and University Colleges, London. Currently, focused ultrasound treatment for both prostate cancer and essential tremor has National Institute for Health and Care Excellence (NICE) approval and National Health Service England (NHS) coverage. 1,2 The technology has 32 regulatory approvals worldwide and is in various stages of research and development for nearly 170 diseases and conditions including Alzheimer’s disease, Parkinson’s disease, metastatic breast tumours, and tumours of the brain, liver, pancreas, and prostate. Launch of the UK FUSF will help enable donations to be applied directly to laboratory research and clinical trials in the UK, accelerating and expanding the exceptional work that has been ongoing for several years. It is hoped this will significantly increase the accessibility to already approved focused ultrasound-based treatments, which currently have limited availability in the UK. Specific areas of focus for the UK FUSF include cancer immunotherapy, brain diseases, pancreatic cancer, prostate cancer, and pediatric applications. “ Our vision at the Foundation is for focused ultrasound to be used in the UK to improve the lives of millions of people afflicted with a wide variety of serious medical disorders in the shortest time possible,” said Foundation Chairman Philip Keevil. “ By identifying opportunities, inspiring collaboration, raising awareness and overcoming barriers, the Foundation will shorten the time from laboratory research to widespread treatment using this remarkable and versatile technology.” The UK FUSF is an independent charity registered with the Charity Commission and HMRC, and GiftAid Eligible. It works closely with, but is independent of, the US-based Focused Ultrasound Foundation, aligning on goals and resources to advance focused ultrasound to treat millions worldwide. The Institute of Cancer Research in the UK was selected in 2013 by the US organization as the second global Focused Ultrasound “Center of Excellence” (there are now only 10 worldwide). UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London. “ I’ve been studying the use of focused ultrasound technology in oncology and have worked with the US Foundation for many years,” said Professor Gail ter Haar of The Institute of Cancer Research. “ The launch of the UK FUSF is an incredibly important milestone. This organisation will further catalyse development and adoption of the technology, bringing much needed innovative new treatments to our community and beyond.” The potential of focused ultrasound to be a game-changing treatment for so many diseases has attracted the attention of celebrities including musician Peter Gabriel, an honorary member of the UK FUSF Advisory Council. Said Mr. Gabriel, “ Sound has been the stuff I work with every day of my life. It’s thrilling to see how powerful it can be when ingeniously applied to healthcare. I’m delighted to see these pioneering technologies take root in the UK.” About the UK Focused Ultrasound Foundation Together with our sister organisation in the US, the UK Focused Ultrasound Foundation is working to provide patients with this noninvasive, life-changing treatment option in the shortest time possible. The UK FUSF will contribute financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. Focused ultrasound research in the UK has been funded by the US Foundation since 2009. For more information visit https://ukfusf.org/ . About Focused Ultrasound Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. It is approved in the UK to treat prostate cancer and essential tremor. Dozens of additional indications are approved elsewhere in the world, including the United States, Europe and Asia. The technology is in various stages of research and development for nearly 170 diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, metastatic breast tumours, and tumours of the brain, liver and pancreas. Click here to watch a 6-minute video about focused ultrasound in the UK. References 1.National Institute for Health and Care Excellence 2005. High-intensity focused ultrasound for prostate cancer. Interventional procedures guidance [IPG118] . Available at: https://www.nice.org.uk/guidance/ipg118/chapter/1-Guidance . Last accessed January 2023. 2. National Institute for Health and Care Excellence 2018. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor. Interventional procedures guidance [IPG617] . Available at: https://www.nice.org.uk/guidance/ipg617/chapter/1-Recommendations . Last accessed January 2023.

LONDON--( BUSINESS WIRE )--The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch. Focused ultrasound is a groundbreaking platform technology that uses ultrasound energy guided by real-time imaging to treat tissue deep in the body, without incisions or radiation. The Foundation will celebrate its launch with an event being held on 31 January at the House of Lords with important guests including MPs, members of the House of Lords, business leaders, and experts from medical charities and some of the UK’s leading research institutions, including the Institute of Cancer Research, Oxford University, and Imperial, King’s and University Colleges, London. Currently, focused ultrasound treatment for both prostate cancer and essential tremor has National Institute for Health and Care Excellence (NICE) approval and National Health Service England (NHS) coverage. 1,2 The technology has 32 regulatory approvals worldwide and is in various stages of research and development for nearly 170 diseases and conditions including Alzheimer’s disease, Parkinson’s disease, metastatic breast tumours, and tumours of the brain, liver, pancreas, and prostate. Launch of the UK FUSF will help enable donations to be applied directly to laboratory research and clinical trials in the UK, accelerating and expanding the exceptional work that has been ongoing for several years. It is hoped this will significantly increase the accessibility to already approved focused ultrasound-based treatments, which currently have limited availability in the UK. Specific areas of focus for the UK FUSF include cancer immunotherapy, brain diseases, pancreatic cancer, prostate cancer, and pediatric applications. “ Our vision at the Foundation is for focused ultrasound to be used in the UK to improve the lives of millions of people afflicted with a wide variety of serious medical disorders in the shortest time possible,” said Foundation Chairman Philip Keevil. “ By identifying opportunities, inspiring collaboration, raising awareness and overcoming barriers, the Foundation will shorten the time from laboratory research to widespread treatment using this remarkable and versatile technology.” The UK FUSF is an independent charity registered with the Charity Commission and HMRC, and GiftAid Eligible. It works closely with, but is independent of, the US-based Focused Ultrasound Foundation, aligning on goals and resources to advance focused ultrasound to treat millions worldwide. The Institute of Cancer Research in the UK was selected in 2013 by the US organization as the second global Focused Ultrasound “Center of Excellence” (there are now only 10 worldwide). UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London. “ I’ve been studying the use of focused ultrasound technology in oncology and have worked with the US Foundation for many years,” said Professor Gail ter Haar of The Institute of Cancer Research. “ The launch of the UK FUSF is an incredibly important milestone. This organisation will further catalyse development and adoption of the technology, bringing much needed innovative new treatments to our community and beyond.” The potential of focused ultrasound to be a game-changing treatment for so many diseases has attracted the attention of celebrities including musician Peter Gabriel, an honorary member of the UK FUSF Advisory Council. Said Mr. Gabriel, “ Sound has been the stuff I work with every day of my life. It’s thrilling to see how powerful it can be when ingeniously applied to healthcare. I’m delighted to see these pioneering technologies take root in the UK.” About the UK Focused Ultrasound Foundation Together with our sister organisation in the US, the UK Focused Ultrasound Foundation is working to provide patients with this noninvasive, life-changing treatment option in the shortest time possible. The UK FUSF will contribute financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. Focused ultrasound research in the UK has been funded by the US Foundation since 2009. For more information visit https://ukfusf.org/ . About Focused Ultrasound Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. It is approved in the UK to treat prostate cancer and essential tremor. Dozens of additional indications are approved elsewhere in the world, including the United States, Europe and Asia. The technology is in various stages of research and development for nearly 170 diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, metastatic breast tumours, and tumours of the brain, liver and pancreas. Click here to watch a 6-minute video about focused ultrasound in the UK. References 1.National Institute for Health and Care Excellence 2005. High-intensity focused ultrasound for prostate cancer. Interventional procedures guidance [IPG118] . Available at: https://www.nice.org.uk/guidance/ipg118/chapter/1-Guidance . Last accessed January 2023. 2. National Institute for Health and Care Excellence 2018. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor. Interventional procedures guidance [IPG617] . Available at: https://www.nice.org.uk/guidance/ipg617/chapter/1-Recommendations . Last accessed January 2023.

DUBLIN--( BUSINESS WIRE )--The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Interventional Oncology Global Market is Expected to Grow at a High Single Digit CAGR from 2019 to 2026 to Reach $2,119.4 Million by 2026 The interventional oncology global market is expected to grow at a high single from 2022 to 2029. Some of the factors driving the market are the increasing prevalence of cancer cases, the increasing geriatric population and the growing adoption of minimally invasive procedures. Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market. Similarly, side effects and risks associated with the use, lack of awareness, and lack of trained professionals are restraining the market growth, While, the availability of alternative treatments and stringent regulatory guidelines are a threat to market growth. The interventional oncology market is segmented based on products, applications, end-users, and geography. The interventional oncology market based on products is segmented as ablation and embolization. The embolization segment is expected to grow at a mid-single from 2022 to 2029. The ablation segment is the fastest-growing double digit from 2022 to 2029. Ablation global market based on product type is sub-segmented into radiofrequency ablation, microwave ablation, Cryoablation, HIFU, and others (irreversible electroporation and MRI-guided laser ablation). Among these, microwave ablation is expected to grow at a double-digit from 2022 to 2029. The HIFU segment is the fastest-growing in high teens from 2022. Embolization global market based on procedure is sub-segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), trans-arterial chemo-embolization (TACE), drug-eluting beads trans-arterial chemo-embolization (DEB-TACE) and trans-arterial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT is expected to grow at a mid-single from 2022 to 2029. The Bland/TAE is the fastest-growing at mid-single from 2022 to 2029. Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. Brain & spine cancer is the fastest-growing at double-digit from 2022. Further, the application market is sub-segmented into ablation and embolization applications. The ablation market is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow double-digit from 2022 to 2029. Brain & spine cancer is the fastest-growing segment with a double-digit from 2022 to 2029. Embolization global market based on application is segmented into liver cancer, lung cancer, prostate cancer, and others. Among embolization applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes. Among end-users, the hospital is expected to grow at a high single from 2022 to 2029. The ambulatory surgical center is the fastest-growing at a high single from 2022 to 2029. North America is expected to be at a high single from 2022 to 2029. Mainly due to increasing incidences of cancer, increasing demand for minimally invasive surgeries, favorable reimbursements, product launches, and availability of skilled personnel. The Asia-Pacific is the fastest-growing region with a double-digit growth rate. Due to the increasing geriatric population and increasing incidence of cancer, increased expenditure on healthcare facilities, increasing awareness about interventional oncology, and low-cost surgery is driving the market. The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Factors Influencing Market Drivers and Opportunities Increasing Incidence of Cancer Cases Growing Adoption of Minimally Invasive Procedures Increasing Geriatric Population Technological Advancements in the Field of Interventional Oncology Expansion in the Emerging Markets Restraints and Threats Side Effects and Risks Associated With the Use Lack of Awareness Lack of Trained Professionals Availability of Alternative Treatments Stringent Regulatory Guidelines Some of the major players in the interventional oncology market include Angiodynamics Inc. Boston Scientific Corporation Cdh Investments (Cdh Gentech Ltd), (Sirtex Ltd.) Guerbet Johnson & Johnson Medtronic, plc Merit Medical Systems, Inc Monteris Medical Siemens Healthineers (Varian Medical) Terumo Corporation Market Share Analysis Interventional Oncology Global Market Share Analysis Io Ablation Global Market Share Analysis Io Embolization Global Market Share Analysis Radiofrequency Ablation Global Market Share Analysis Io Microwave Ablation Global Market Share Analysis Io Tare Global Market Share Analysis Io Deb-Tace Global Market Share Analysis Io Tae Global Market Share Analysis Interventional Oncology Global Market, Based on Product Ablation Radiofrequency Ablation Microwave Ablation Cryoablation High-Intensity Focused Ultrasound (Hifu) Other Ablation Embolization Io Trans-Arterial Radio-Embolization(Tare)/ Selective Internal Radiation Therapy (Sirt) Io Transarterial Chemo-Embolization (Tace) Io Drug-Eluting Beads Transarterial Chemo-Embolization (Deb-Tace) Io Bland Embolization/ Transarterial Embolization (Tae) Interventional Oncology Global Market, Based on Application Liver Cancer Kidney Cancer Lung Cancer Brain and Spine Cancer Prostate Cancer Other Applications Regulatory Affairs International Organization for Standardization Iso 9001: 2015 Quality Management System Iso:13485 Medical Devices Iso 10993 Biological Evaluation of Medical Devices Iso 14971 Risk Management of Medical Devices Iso 12807:2018 Safe Transport of Radioactive Materials- Leakage Testing on Packages Iec 60601-1 Medical Electrical Equipment Standard Iec 60601-1-2 Electromagnetic Compatibility (Emc) for Medical Devices U.S. Canada Europe Japan China India Companies Mentioned Accutarget Medipharma (Shanghai) Co. Ltd Angiodynamics, Inc. Balt Group Boston Scientific Corporation Bvm Medical Limited Changi Jianyuan Technology Development Clinical Laserthermia Systems Cook Medical Creo Medical Ltd Diros Technology Inc. Eco Medical Edap Tms Guerbet Haifu Medical Ice Cure Medical Imbiotechnologies Ltd Insightec Johnson & Johnson Medtronic, plc Medwaves, Inc. Merit Medical Systems Mianyang Sonic Electronic Monteris Medical Nanospectra Biosciences, Inc. Novian Health, Inc Olympus Corporation Pharmacept GmbH Profound Medical Corporation Quantum Surgical Rbc Medical Innovations Scitech Medical Shenzhen Huikang Medical Apparatus Co. Ltd. (Wikkon) Siemens Healthineers (Varian) Sirtex Medical Limited/Cdh Sonablate Corp. Starmed Co. Ltd. Surgnova Healthcare Technologies (Zhejiang) Co. Ltd. Symple Surgery Teleflex Incorporated Terumo Corporation For more information about this report visit https://www.researchandmarkets.com/r/b0hcna